Scientists have invented an antibiotic against superbugs

Scientists have invented a new antibiotic – cresomycin – that can successfully fight persistent “superbugs”, reports The Financial Times, citing an article published in the journal Science.

function news4059813() {
$.get(‘//’ + window.location.host + ‘/ajax/module.aspx?spm_id=444&id=4059813&lang=2&IsAjax=true’, function (data) { $(‘#nk4059813’).html(data); });
}

news4059813();

It was noted that the new antibiotic showed effectiveness in studies in mice against some bacteria that cause serious infections and are becoming increasingly resistant to current treatments.

“The most important thing is that it kills antibiotic-resistant strains in animals.

The synthesis of cresomycin is part of research aimed at overcoming antimicrobial resistance (AMR), which occurs when bacteria, viruses, fungi and parasites develop the ability to resist treatment.

AMR, largely caused by overuse of antibiotics, already causes five million deaths each year, according to the World Health Organization.

Krezomycin has been shown to be effective against a number of dangerous bacteria that play an important role in the spread of acute respiratory resistance, the article says. These include Staphylococcus aureus, which causes infections of the skin and other organs; Escherichia coli (E-coli), which is responsible for intestinal and urinary tract disease, and Pseudomonas aeruginosa, which causes blood and lung infections.

Doctors have long used drugs derived from natural products, such as penicillins and cephalosporins derived from molds, but they are becoming less effective as pathogens evolve to overcome them.

The authors of the cresomycin paper acknowledge that the antibiotic problem is “complex” but say their findings offer hope for the future discovery of antibacterial drugs that will be effective against the antibiotic. -resistant Staphylococcus aureus pathogen.

According to Polikanov, the researchers based cresomycin on an existing antibiotic, but modified it and added additional functions to cope with the changes that AMR brought to its target pathogens.

However, until the new antibiotic is thoroughly studied, it is difficult to predict its value against serious gram-negative infections as a single therapeutic agent.

Currently, the Swiss pharmaceutical company Roche is conducting the first phase of clinical trials of the antibiotic.

It was previously reported that drug-resistant infections are spreading in Ukraine. An example was given by a wounded soldier who was found to have six types of drug-resistant bacteria.

We remind you that in August 2022, electronic prescriptions for antibiotics began to be introduced in Ukraine. This is the first step in the fight against antibiotic resistance caused by the irrational use of antibiotics without a prescription.